Cytek Biosciences, Inc. (CTKB) Misses Q1 EPS by 7c, Misses on Revenue; Offers FY25 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. META
6. SPY
7. INTC
8. JBLU
9. NVDA
10. BA

Go back to Cytek Biosciences, Inc. (CTKB) Misses Q1 EPS by 7c, Misses on Revenue; Offers FY25 Revenue Guidance

Cytek Biosciences Reports First Quarter 2025 Financial Results

May 8, 2025 4:06 PM EDT

FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (Cytek Biosciences or Cytek) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025.

First Quarter Highlights

Total revenue for the first quarter of 2025 was $41.5 million, representing a 7.6% decrease compared to the first quarter of 2024Expanded to a total installed base of 3,149 Cytek instruments, including the Amnis® and Guava® instruments shipped since the acquisition of the product lines in February 2023, adding 115 units in the first quarter of 2025Commenced operations in Singapore to access... More